论文部分内容阅读
目的探讨血清表皮生长因子(EGF)在慢性肝病和原发性肝癌患者中的测定及临床意义。方法 48例慢性肝病患者、20例原发性肝癌患者以及50例门诊健康体检患者(对照组)作为研究对象,采用放射免疫法对患者治疗前后EGF的含量变化进行测定。结果各种肝病患者血清中的EGF含量均明显低于对照组患者,差异具有统计学意义(P<0.05)。同时EGF的含量随着患者肝病严重程度的增加而降低,各种肝病患者间比较差异有统计学意义(P<0.05)。治疗与治疗前相比,不同肝病患者血清中的EGF含量均明显增加。结论血清中EGF水平的改变对肝病严重程度的衡量及预后情况的判断具有重要的临床意义,在早期肝癌的诊断方面具有一定的临床价值。
Objective To investigate the serum level of epidermal growth factor (EGF) in patients with chronic liver disease and primary liver cancer and its clinical significance. Methods 48 patients with chronic liver disease, 20 patients with primary hepatocellular carcinoma and 50 patients with outpatient health examination (control group) were studied. The content of EGF in the patients before and after treatment was measured by radioimmunoassay. Results The serum levels of EGF in patients with various liver diseases were significantly lower than those in the control group (P <0.05). At the same time, the content of EGF decreased with the severity of liver disease in patients, and there was significant difference among various liver diseases (P <0.05). Compared with before treatment, serum EGF levels in patients with different liver diseases were significantly increased. Conclusion The change of serum EGF level has important clinical significance in the measurement of severity of liver disease and prognosis, and has certain clinical value in the diagnosis of early liver cancer.